Watson-Marlow Fluid Technology Group has acquired Asepco through its parent company Spirax-Sarco Engineering, for £7.0 million. Asepco, based in CA, specializes in the design and manufacture of high purity aseptic valves and magnetic mixers for the bioprocessing industry.
 
Asepco expands Watson-Marlow’s fluid path product portfolio and global presence in the biotechnology and pharmaceutical industries. Asepco uses patented technology to improve sterility levels within the biotechnology production process aimed at reducing the risks surrounding validation in demanding contamination-free applications.
 
Jay Whalen, president of the Watson-Marlow Fluid Technology Group, said, “The strategic acquisition of Asepco further broadens our product range and strengthens Watson-Marlow’s position in the biopharmaceutical market. This enables us to provide a more comprehensive and improved service to our customers looking for sterility throughout their fluid path. This is another exciting milestone for Watson-Marlow and we are looking forward to accelerating our growth within the biopharmaceutical market with our broadened product portfolio coupled to our process expertise.”
 
Steve Joy, Asepco’s president will remain in his role. Mr. Joy said, “I am very excited to be part of the Watson-Marlow Fluid Technology Group and look to drive sales further with the expansive WMFTG sales network.”